Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate

Journal of Cardiovascular Pharmacology

Volumn 38, Issue 2, 2001, Pages 250-258

  Meco, José Félix ^a   Vila, Ramón ^a   Pujol, Ramon ^a   Bros, Rafael ^a   Doménech, Pere ^a   Fiol, Concepción ^a   Pintó, Xavier ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bezafibrate; Brachial artery ultrasound study; Coronary artery disease; Endothelial dysfunction; Fibrinogen; Low high density lipoprotein cholesterol

Indexed keywords

APOLIPOPROTEIN A1; BEZAFIBRATE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BRACHIAL ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPEREMIA; HYPOLIPOPROTEINEMIA; MALE; PRIORITY JOURNAL; RISK FACTOR; ULTRASOUND THERAPY;

EID: 0034917493     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200108000-00011     Document Type: Article

References (40)

1. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
2. Coronary atherosclerotic wall thickening and vascular reactivity in humans: Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis
3. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men
4. Oxidized lipoproteins inhibit endothelium-dependent vasodilation: Effects of pressure and high-density lipoprotein
5. LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture
6. Role of high density lipoproteins in the regression of atherosclerosis
7. Endothelial dysfunction: Does it matter? Is it reversible?
8. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease
9. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
10. Non-invasive measurement of endothelial function: Effect on brachial artery dilatation of graded endothelial dependent and independent stimuli
11. Close relation of endothelial function in the human coronary and peripheral circulations
12. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease
13. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol
14. Cholesterol lowering and endothelial function
15. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
16. Non-invasive measurement of human endothelium dependent arterial responses: Accuracy and reproducibility
17. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
18. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
19. Improvement of endothelium-dependent coronary vasomotion by cholesterol lowering in patients with hypercholesterolemia
20. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
21. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia
22. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate
23. Effect of gemfibrozil ± niacin cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels < 160 mg/dl and high-density lipoprotein cholesterol levels < 40 mg/dl
24. Does lipoprotein(a) impair endothelial function?
25. Homocysteine and atherothrombosis
26. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis
27. Impaired endothelial function in patients with rapidly stabilized unstable angina: Assessment by noninvasive brachial artery ultrasonography
28. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (REduction of Cholesterol in Ischemia and Function of the Endothelium) trial
29. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
30. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans
31. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease
32. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels
33. Cholesterol and lipids in the risk of coronary artery disease: The Framingham Heart Study
34. Impact of management in stabilization of coronary disease
35. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly
36. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
37. Bezafibrate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia
38. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
39. Fibrinogen is a predictor of mortality in coronary heart disease patients
40. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris